Home
½ÃÀÛÆäÀÌÁö
Áö³È£º¸±â
·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
±¸µ¶½Åû
Àüü±â»ç
2024-03-29 ±Ý 20:27
±â»ç°Ë»ö
Cover Story
¼øȯ±â
³»ºÐºñ
È£Èí±â
¼Òȱâ
½Å°æ°ú
Á¤½Å°Ç°
°¨¿°³»°ú
Sub Story
Interview
Drug Review
Conference Report
Late Breaking Studies
Expert Opinion
Primary Expert Opinion
The Rare Disease
ÇмúÀÚ¹®À§¿ø
RTM
»ó´Ü¿©¹é
񃯇
(Àüü 35°Ç)
Á¦¸ñº¸±â
Á¦¸ñº¸±â
Á¦¸ñ+³»¿ë
[Sub Story]
1Â÷Ä¡·á ´ëü¿ª·® UP
ÀÌ»óµ· ±âÀÚ
2020-07-26 19:25
[Sub Story]
ADA Guideline Says...
ÀÌ»óµ· ±âÀÚ
2020-07-26 19:12
[Cover Story]
Á¦2Çü´ç´¢º´ 1Â÷Ä¡·á Æз¯´ÙÀÓ
½Å¾à¡¤±¸¾à ´ç±Ç ³õ°í ÇÑÆÇ
ÀÌ»óµ· ±âÀÚ
2020-07-26 18:37
[Sub Story]
Ç÷´ç¡¤Ã¼Áß¡¤Ç÷¾Ð¡¤ÀúÇ÷´çÁõ¿¡ ¸ÞÆ®Æ÷¸£¹Î À¯È¿¼º¡¤¾ÈÀü¼ºÀº?
ÀÌ»óµ· ±âÀÚ
2020-07-26 18:15
[Sub Story]
1Â÷Ä¡·á ¼º°ø·ü °¡Àå ³ô¾Æ
ÀÌ»óµ· ±âÀÚ
2020-07-26 18:09
¶óÀÎ
[Interview]
¡°¸ÞÆ®Æ÷¸£¹Î, 1Â÷Ä¡·á¿¡ °ÇÀçÇÔ º¸¿©Áࡱ
ÀÌ»óµ· ±âÀÚ
2020-07-26 18:01
[Sub Story]
Çѱ¹µµ ½ÉÇ÷°ü ÇýÅÿ¡ Â÷º°È ±Ç°í
ÀÌ»óµ· ±âÀÚ
2020-07-26 17:42
[Sub Story]
¿¥Æı۸®Ç÷ÎÁø Ä¡·áŸ±ê »ïÇüÁ¦
ÀÌ»óµ· ±âÀÚ
2020-07-26 17:37
[Sub Story]
¡°ºñ¸¸¡¤´ç´¢º´ ȯÀÚ¿¡ SGLT-2i ±Ç°í¡±
THE MOST
2020-07-26 17:21
[Sub Story]
Çѱ¹ÀÎÀº º´¿ëÀÌ ´õ ÀûÇÕÇÏ´Ù?
ÀÌ»óµ· ±âÀÚ
2020-07-26 17:18
¶óÀÎ
[Sub Story]
Çѱ¹ÀÎ Ç÷´ç°ÇÏÁ¦ ó¹æ º¸´Ï¡¦
ÀÌ»óµ· ±âÀÚ
2020-07-26 17:15
[Sub Story]
¸ÞÆ®Æ÷¸£¹Î¿¡ ´õÇÒ º¸¹°Ã£±â ÇÑâ
ÀÌ»óµ· ±âÀÚ
2020-07-26 00:22
[Sub Story]
¡°Ã³À½ºÎÅÍ º´¿ëÇ϶ó¡±
ÀÓ¼¼Çü ±âÀÚ
2020-07-26 00:07
[Sub Story]
¿¥Æı۸®Ç÷ÎÁø¡¤¸®³ª±Û¸³Æ¾¡¤¸ÞÆ®Æ÷¸£¹Î
ÀÌ»óµ· ±âÀÚ
2020-07-25 23:20
[Sub Story]
4Â÷Ä¡·á¿¡µµ °æ±¸Á¦ ÅÃÇß´õ´Ï¡¦
ÀÌ»óµ· ±âÀÚ
2020-07-25 23:01
¶óÀÎ
[Sub Story]
Á¦¹Ì±Û¸³Æ¾+¸ÞÆ®Æ÷¸£¹Î Ãʱ⺴¿ë,
Ç÷´ç ¼öÄ¡¡¤º¯µ¿¼º °³¼±¿¡ ¡®È¿°úÀû¡¯
ÀÓ¼¼Çü ±âÀÚ
2020-07-25 17:01
[Drug Review]
ÇÁ¸®½ºÅ¸ÀÏ ¸®ºê·¹, Ç÷´çº¯µ¿¼º °ü¸®Àü·«À¸·Î ºÎ°¢
ÀÓ¼¼Çü ±âÀÚ
2020-07-25 15:01
[Interview]
Ç÷´çº¯µ¿¼º °ü¸®ÀÇ ½Ã´ë, ¿¬¼ÓÇ÷´çÃøÁ¤(CGM)ÀÌ ÇعýµÈ´Ù
ÀÓ¼¼Çü ±âÀÚ
2020-07-25 14:45
[Drug Review]
Ç÷´ç¡¤ÄÝ·¹½ºÅ×·Ñ µ¿½Ã°ø·« ¼øÀÀµµ ÀÌ»ó¹«
ÀÌ»óµ· ±âÀÚ
2020-07-25 14:24
[Expert Opinion]
°íÇ÷¾Ð Ä¡·á¿Í Áø´Ü¿¡ ´Ù°¡¿À´Â µÎ °¡Áö ¹Ì·¡
THE MOST
2020-07-25 14:07
-
1
2
-
¿©¹é
Sub
news
¡°ACEI ÀÓ»ó±Ù°Å ³õ°í, ȯÀÚ ¼³µæÇÏÀÚ¡±
Q. Ç÷¾Ð°ÇÏ Ãø¸é¿¡¼ ACEIÀÇ Æ¯¼ºÀº?ù...
¡°SGLT-2i Ȳ±Ý±â´Â TZD¿Í º´¿ëÀ¸·ÎºÎÅÍ¡±
Q. SGLT-2iÀÇ °è¿È¿°ú¿¡ ´ëÇÑ °ßÇØ´Â...
¡°°í°µµ ½ºÅ¸Æ¾ Á¦Á¦ È¿°ú ´ëµîÇϳª ¾ÈÀü¼º ´Ù¸¦ ¼öµµ¡±
Q. CAD ȯÀÚÀÇ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÀü·«Àº?...
¿©¹é
¿©¹é
Back to Top